One-Time radiation during breast surgery: can imaging pick the right patients?
NCT ID NCT00556907
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether mammography and breast MRI could help identify patients with early-stage breast cancer (DCIS) who could safely receive a single dose of radiation during surgery, instead of weeks of daily radiation afterward. The goal was to avoid repeat surgeries and extra radiation. The trial was stopped early after enrolling 36 people, so the findings are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Intraoperative radiotherapy (radiation given during surgery)
- What this could lead to
- If successful, this approach could reduce the need for repeat surgeries and additional radiation in some breast cancer patients.
- What could go wrong
- The trial was terminated early with only 36 participants, so results are limited. It is unclear if the method works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
36 people
The number who actually took part.
- Started
-
Oct 2007
- Finished
-
Nov 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with biopsy-proven DCIS, mammographic and CE-MRI evidence of DCIS measuring great then equal to 4cm, and a desire to receive breast conserving therapy, will be considered for participation in this study. * Patient history, physical examination findings, and demographics (sex, age, height, weight, bra size, etc.) will be performed and documented. Inclusion Criteria for Initial Registration (all patients cohorts): All cohorts * Signed informed consent and HIPAA documents * Female sex * Age great then equal to 40 years * Localized ductal carcinoma in situ * Clinically and/or histologically negative axillary lymph nodes * No imaging or clinical findings suggestive of invasive carcinoma. Cohort 1 (Immediate IORT group) * Localized DCIS measuring less then equal to 4 cm on preoperative imaging. * Cohort 2 (Delayed IORT group) * Localized DCIS measuring less then equal to4 cm or less on surgical pathology * Delayed IORT could be performed for the explicit purpose of administering IORT or performed following re-excision of a previously operated breast to achieve clear surgical margins. * This cohort includes patients who were excluded from immediate IORT based on pre-operative imaging suggesting ineligibility for immediate IORT, but who are subsequently found to meet histological criteria (localized DCIS less then equal to 4 cm and no invasive cancer) for IORT based on surgical pathology. * Unifocal microinvasive (T1mic or invasive focus less then equal to 1mm in maximal diameter) is allowed following initial WLE if surgical pathology margins were less then equal to2 mm for both the invasive and non-invasive components. * Delayed IORT must be performed within 3 months of initial WLE. * Cohort 3 Subjects who received IORT at the time of initial WLE but whose surgical pathology showed them to be unsuitable candidates for IORT alone on the basis of: * DCIS measuring greater than 5 cm on surgical pathology. * T1a (less than 1 mm) or larger invasive carcinoma associated with extensive DCIS. * Surgical margins width less than1 mm. Exclusion Criteria: * Male sex * Age less than 40 * DCIS associated with any evidence of microinvasion or invasive carcinoma on pre-operative imaging or core biopsy of the breast or axillary nodes. * DCIS that is multicentric in the ipsilateral breast. Multicentricity will be defined at 2 or more lesions separated by more than 3 cm in the same breast. * Non-epithelial breast malignancies such as sarcoma or lymphoma * DCIS associated with diffuse suspicious or indeterminate microcalcifications * Pregnancy or lactation * Collagen vascular diseases, including Systemic lupus erythematosus, Systemic sclerosis (scleroderma), CREST Syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia, and the presence of anticentromere antibodies), polymyositis, dermatomyositis with a CPK level above normal or with an active skin rash, inclusion-body myositis, or amyloidosis * Serious psychiatric or addictive disorders
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?